BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Amôr NG, de Oliveira CE, Gasparoto TH, Vilas Boas VG, Perri G, Kaneno R, Lara VS, Garlet GP, da Silva JS, Martins GA, Hogaboam C, Cavassani KA, Campanelli AP. ST2/IL-33 signaling promotes malignant development of experimental squamous cell carcinoma by decreasing NK cells cytotoxicity and modulating the intratumoral cell infiltrate. Oncotarget 2018;9:30894-904. [PMID: 30112116 DOI: 10.18632/oncotarget.25768] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Mantovani A, Dinarello CA, Molgora M, Garlanda C. Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity. Immunity 2019;50:778-95. [PMID: 30995499 DOI: 10.1016/j.immuni.2019.03.012] [Cited by in Crossref: 191] [Cited by in F6Publishing: 178] [Article Influence: 63.7] [Reference Citation Analysis]
2 Alyoussef A, Taha M. Blocking Wnt as a therapeutic target in mice model of skin cancer. Arch Dermatol Res 2019;311:595-605. [PMID: 31165240 DOI: 10.1007/s00403-019-01939-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
3 Salvo E, Tu NH, Scheff NN, Dubeykovskaya ZA, Chavan SA, Aouizerat BE, Ye Y. TNFα promotes oral cancer growth, pain, and Schwann cell activation. Sci Rep 2021;11:1840. [PMID: 33469141 DOI: 10.1038/s41598-021-81500-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Azin M, Demehri S. Innate Lymphoid Cells: New Targets for Cutaneous Squamous Cell Carcinoma Immunotherapy. J Invest Dermatol 2021;141:2320-2. [PMID: 34560914 DOI: 10.1016/j.jid.2021.04.003] [Reference Citation Analysis]
5 Bottomley MJ, Thomson J, Harwood C, Leigh I. The Role of the Immune System in Cutaneous Squamous Cell Carcinoma. Int J Mol Sci 2019;20:E2009. [PMID: 31022866 DOI: 10.3390/ijms20082009] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 11.0] [Reference Citation Analysis]
6 Amôr NG, Santos PSDS, Campanelli AP. The Tumor Microenvironment in SCC: Mechanisms and Therapeutic Opportunities. Front Cell Dev Biol 2021;9:636544. [PMID: 33634137 DOI: 10.3389/fcell.2021.636544] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Gao X, Chi X, Wang X, Wu R, Xu H, Zhan M, Li D, Ding Y, Xu D, Niu J. IL-33 Inhibits Hepatitis B Virus through Its Receptor ST2 in Hydrodynamic HBV Mouse Model. Mediators Inflamm 2020;2020:1403163. [PMID: 32410845 DOI: 10.1155/2020/1403163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Alyoussef A. Evaluating antitumor activity of antiglypican-3 therapy in experimentally induced skin cancer in mice. Arch Dermatol Res 2021;313:263-73. [PMID: 32638071 DOI: 10.1007/s00403-020-02102-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Suga Y, Nagatomo I, Kinehara Y, Koyama S, Okuzaki D, Osa A, Naito Y, Takamatsu H, Nishide M, Nojima S, Ito D, Tsuda T, Nakatani T, Nakanishi Y, Futami Y, Koba T, Satoh S, Hosono Y, Miyake K, Fukushima K, Shiroyama T, Iwahori K, Hirata H, Takeda Y, Kumanogoh A. IL-33 Induces Sema4A Expression in Dendritic Cells and Exerts Antitumor Immunity. J Immunol 2021;207:1456-67. [PMID: 34380650 DOI: 10.4049/jimmunol.2100076] [Reference Citation Analysis]